Association Between SCN1A Polymorphism Rs3812718 and Valproic Acid Resistance in Epilepsy Children: a Case-control Study and Meta-analysis

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2018 Nov 11

PMID 30413604

Citations 8

Authors

Zhi Jian Wang

Jie Chen

Hai Liang Chen

Lin Yan Zhang

Duo Xu

Wen Ting Jiang

Affiliations

Soon will be listed here.

Abstract

Resistance to valproic acid (VPA), a first-line antiepileptic drug (AED), is occurring at an alarming rate, particularly in children. Signal nucleotide polymorphisms are considered crucial in this process. Therefore, we investigated whether the SCN1A polymorphism rs3812718 could be associated with VPA resistance. A total of 231 children with epilepsy who were solely administered VPA were enrolled. DNA was extracted from the peripheral blood samples and was genotyped by the Mass Array method. Furthermore, a meta-analysis was conducted between the drug responsive and resistant patients who were exposed to voltage-gated sodium channels. Results revealed that the TT genotype was associated with a higher risk of developing drug resistance (OR = 2.636, 95% CI 1.08-6.433, = 0.033). After adjusting for the risk factors, a significant difference was still observed between the responsive and resistant groups (OR = 2.861, 95% CI 1.141-7.174, = 0.025). Moreover, the recessive model was associated with a decreased drug resistance (OR = 0.402, 95% CI 0.167-0.968, = 0.042) after correcting the risk factors. Meta-analysis of nine studies revealed similar results. In conclusion, our results proved that the rs3812718 TT genotype was associated with a high risk of developing drug resistance, and the recessive model could decrease the risk of VPA resistance.

Citing Articles

Sodium channel mutation T875M, D188V and associated dysfunction with drug resistant epilepsy.

Dabla P, Gupta S, Singh S, Viswas A, Yadav M, Sonkar S World J Psychiatry. 2025; 15(2):100738.

PMID: 39974498 PMC: 11758033. DOI: 10.5498/wjp.v15.i2.100738.

Association of Polymorphisms rs3812718 and rs2298771 with Epilepsy.

Katsarou M, Siatouni A, Tsikrika D, Kokkiou E, Stefanatou M, Verentzioti A Genes (Basel). 2024; 15(9).

PMID: 39336815 PMC: 11431656. DOI: 10.3390/genes15091224.

Association of genetic variants with autism spectrum disorder in Japanese children revealed by targeted sequencing.

Shiota Y, Nishiyama T, Yokoyama S, Yoshimura Y, Hasegawa C, Tanaka S Front Genet. 2024; 15:1352480.

PMID: 39280100 PMC: 11395840. DOI: 10.3389/fgene.2024.1352480.

Single-Base Gene Variants in and Genes Related to the Epileptogenic Process in Drug-Responsive and Drug-Resistant Temporal Lobe Epilepsy-A Preliminary Study in a Brazilian Cohort Sample.

Buainain R, Sodre A, Dos Santos J, Takazaki K, de Souza Queiroz L, de Oliveira C Int J Mol Sci. 2024; 25(11).

PMID: 38892194 PMC: 11172889. DOI: 10.3390/ijms25116005.

Association between Genetic Polymorphism of , and and Drug Responsiveness in Vietnamese Epileptic Children.

Tang H, Ho M, Vu N, Cao H, Ngo V, Nguyen V Medicina (Kaunas). 2024; 60(4).

PMID: 38674283 PMC: 11052159. DOI: 10.3390/medicina60040637.

References

Perucca E . Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002; 16(10):695-714. DOI: 10.2165/00023210-200216100-00004. View

Tate S, Depondt C, Sisodiya S, Cavalleri G, Schorge S, Soranzo N . Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005; 102(15):5507-12. PMC: 556232. DOI: 10.1073/pnas.0407346102. View

Tate S, Singh R, Hung C, Tai J, Depondt C, Cavalleri G . A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006; 16(10):721-6. DOI: 10.1097/01.fpc.0000230114.41828.73. View

Shahwan A, Murphy K, Doherty C, Cavalleri G, Muckian C, Dicker P . The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 2006; 73(2):192-8. DOI: 10.1016/j.eplepsyres.2006.10.004. View

Heinzen E, Yoon W, Tate S, Sen A, Wood N, Sisodiya S . Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet. 2007; 80(5):876-83. PMC: 1852745. DOI: 10.1086/516650. View

Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K . Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 2008; 66(2):304-7. PMC: 2492927. DOI: 10.1111/j.1365-2125.2008.03203.x. View

Kwan P, Poon W, Ng H, Kang D, Wong V, Ng P . Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics. 2008; 18(11):989-98. DOI: 10.1097/FPC.0b013e3283117d67. View

Kwan P, Arzimanoglou A, Berg A, Brodie M, Hauser W, Mathern G . Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009; 51(6):1069-77. DOI: 10.1111/j.1528-1167.2009.02397.x. View

Sanchez M, Herranz J, Leno C, Arteaga R, Oterino A, Valdizan E . Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010; 19(2):93-101. DOI: 10.1016/j.seizure.2009.12.004. View

10.

Thompson C, Kahlig K, George Jr A . SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia. 2011; 52(5):1000-9. PMC: 3093448. DOI: 10.1111/j.1528-1167.2011.03040.x. View

11.

Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y . Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 2011; 21(1):27-30. DOI: 10.1016/j.yebeh.2011.02.015. View

12.

Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U . A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia. 2011; 52(5):e40-4. DOI: 10.1111/j.1528-1167.2011.03097.x. View

13.

Zhou B, Zhou Q, Yin J, Li G, Xu X, Qu J . Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol. 2012; 39(4):379-84. DOI: 10.1111/j.1440-1681.2012.05680.x. View

14.

Haerian B, Baum L, Tan H, Kwan P, Raymond A, Saruwatari J . SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics. 2012; 13(13):1477-85. DOI: 10.2217/pgs.12.127. View

15.

Kumari R, Lakhan R, Kumar S, Garg R, Misra U, Kalita J . SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie. 2013; 95(6):1350-3. DOI: 10.1016/j.biochi.2013.02.006. View

16.

Fisher R, Acevedo C, Arzimanoglou A, Bogacz A, Cross J, Elger C . ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014; 55(4):475-82. DOI: 10.1111/epi.12550. View

17.

Aneja S, Jain P . Refractory epilepsy in children. Indian J Pediatr. 2014; 81(10):1063-72. DOI: 10.1007/s12098-014-1533-1. View

18.

Zhou L, Cao Y, Long H, Long L, Xu L, Liu Z . ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. Pharmazie. 2015; 70(6):416-20. View

19.

Rosati A, De Masi S, Guerrini R . Antiepileptic Drug Treatment in Children with Epilepsy. CNS Drugs. 2015; 29(10):847-63. PMC: 4636994. DOI: 10.1007/s40263-015-0281-8. View

20.

Nakashima H, Oniki K, Nishimura M, Ogusu N, Shimomasuda M, Ono T . Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis. PLoS One. 2015; 10(10):e0141266. PMC: 4617862. DOI: 10.1371/journal.pone.0141266. View